Comparison of the pharmacokinetic characteristics, safety and tolerability of JL14002 monoclonal antibody injection and ranibizumab injection in patients with wet age-related macular degeneration (wAMD) phase clinical trial
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema; Wet age-related macular degeneration
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms CTR20213255; JL14002-001
Most Recent Events
- 10 Jul 2023 New trial record